168 related articles for article (PubMed ID: 37894844)
1. Small Molecule Pytren-4QMn Metal Complex Slows down Huntington's Disease Progression in Male zQ175 Transgenic Mice.
Merino M; González S; Tronch MC; Sánchez-Sánchez AV; Clares MP; García-España A; García-España E; Mullor JL
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894844
[TBL] [Abstract][Full Text] [Related]
2. Mn(II) Quinoline Complex (4QMn) Restores Proteostasis and Reduces Toxicity in Experimental Models of Huntington's Disease.
Merino M; Sequedo MD; Sánchez-Sánchez AV; Clares MP; García-España E; Vázquez-Manrique RP; Mullor JL
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012207
[TBL] [Abstract][Full Text] [Related]
3. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
Elife; 2021 Apr; 10():. PubMed ID: 33871358
[TBL] [Abstract][Full Text] [Related]
5. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
[TBL] [Abstract][Full Text] [Related]
7. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
8. mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease.
Ast A; Buntru A; Schindler F; Hasenkopf R; Schulz A; Brusendorf L; Klockmeier K; Grelle G; McMahon B; Niederlechner H; Jansen I; Diez L; Edel J; Boeddrich A; Franklin SA; Baldo B; Schnoegl S; Kunz S; Purfürst B; Gaertner A; Kampinga HH; Morton AJ; Petersén Å; Kirstein J; Bates GP; Wanker EE
Mol Cell; 2018 Sep; 71(5):675-688.e6. PubMed ID: 30193095
[TBL] [Abstract][Full Text] [Related]
9. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
10. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
[TBL] [Abstract][Full Text] [Related]
11. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease.
Kacher R; Lamazière A; Heck N; Kappes V; Mounier C; Despres G; Dembitskaya Y; Perrin E; Christaller W; Sasidharan Nair S; Messent V; Cartier N; Vanhoutte P; Venance L; Saudou F; Néri C; Caboche J; Betuing S
Brain; 2019 Aug; 142(8):2432-2450. PubMed ID: 31286142
[TBL] [Abstract][Full Text] [Related]
12. Understanding the role of the hematopoietic niche in Huntington's disease's phenotypic expression: in vivo evidence using a parabiosis model.
Rieux M; Alpaugh M; Salem S; Siddu A; Saint-Pierre M; Denis HL; Rohweder H; Herrmann F; Bazenet C; Lacroix S; Cicchetti F
Neurobiol Dis; 2023 May; 180():106091. PubMed ID: 36967065
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.
Fisher SP; Schwartz MD; Wurts-Black S; Thomas AM; Chen TM; Miller MA; Palmerston JB; Kilduff TS; Morairty SR
Sleep; 2016 Feb; 39(2):379-91. PubMed ID: 26446107
[TBL] [Abstract][Full Text] [Related]
14. Withaferin A Induces Heat Shock Response and Ameliorates Disease Progression in a Mouse Model of Huntington's Disease.
Joshi T; Kumar V; Kaznacheyeva EV; Jana NR
Mol Neurobiol; 2021 Aug; 58(8):3992-4006. PubMed ID: 33904021
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease.
Ban JJ; Chung JY; Lee M; Im W; Kim M
Biochem Biophys Res Commun; 2017 Jun; 488(2):316-321. PubMed ID: 28495533
[TBL] [Abstract][Full Text] [Related]
16. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study.
Carty N; Berson N; Tillack K; Thiede C; Scholz D; Kottig K; Sedaghat Y; Gabrysiak C; Yohrling G; von der Kammer H; Ebneth A; Mack V; Munoz-Sanjuan I; Kwak S
PLoS One; 2015; 10(4):e0123527. PubMed ID: 25859666
[TBL] [Abstract][Full Text] [Related]
17. Meso scale discovery-based assays for the detection of aggregated huntingtin.
Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
19. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
20. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
